

**产品名称：胍法辛盐酸盐**  
**产品别名：盐酸胍法辛； Guanfacine hydrochloride**

<b>生物活性：</b>																												
<b>Description</b>	Guanfacine hydrochloride, an anti-hypertensive agent, is a selective $\alpha$ 2A-adrenoceptor agonist with $K_d$ of 31 nM and displays 60-fold selectivity over $\alpha$ 2B-adrenoceptors. IC <sub>50</sub> Value: 31 nM( $K_d$ ) Target: Adrenergic Receptor Guanfacine is a sympatholytic. It is a selective $\alpha$ 2A receptor agonist. These receptors are concentrated heavily in the prefrontal cortex and the locus coeruleus, with the potential to improve attention resulting from interaction with receptors in the former. Guanfacine lowers both systolic and diastolic blood pressure by activating the central nervous system $\alpha$ 2A norepinephrine autoreceptors, which results in reduced peripheral sympathetic outflow and thus a reduction in peripheral sympathetic tone. From Wikipedia.																											
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : <math>\geq</math> 30 mg/mL (106.18 mM)</p> <p>* "<math>\geq</math>" means soluble, but saturation unknown.</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="2"></th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Concentration</th> <th></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Preparing</td> <td>1 mM</td> <td>3.5392 mL</td> <td>17.6960 mL</td> <td>35.3920 mL</td> </tr> <tr> <td style="text-align: center;">Stock Solutions</td> <td>5 mM</td> <td>0.7078 mL</td> <td>3.5392 mL</td> <td>7.0784 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.3539 mL</td> <td>1.7696 mL</td> <td>3.5392 mL</td> </tr> </tbody> </table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。</p> <p>1. 请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline  <b>Solubility:</b> <math>\geq</math> 2.5 mg/mL (8.85 mM); Clear solution  此方案可获得 <math>\geq</math> 2.5 mg/mL (8.85 mM, 饱和度未知) 的澄清溶液。  以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中，混合均匀；向上述体系中加入 50 <math>\mu</math>L Tween-80，混合均匀；然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-<math>\beta</math>-CD in saline)  <b>Solubility:</b> <math>\geq</math> 2.5 mg/mL (8.85 mM); Clear solution  此方案可获得 <math>\geq</math> 2.5 mg/mL (8.85 mM, 饱和度未知) 的澄清溶液。  以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-<math>\beta</math>-CD 生理盐水溶液中，混合均匀。</p> <p>3. 请依序添加每种溶剂： 10% DMSO → 90% corn oil  <b>Solubility:</b> <math>\geq</math> 2.5 mg/mL (8.85 mM); Clear solution</p>						Solvent	Mass	1 mg	5 mg	10 mg	Concentration		Preparing	1 mM	3.5392 mL	17.6960 mL	35.3920 mL	Stock Solutions	5 mM	0.7078 mL	3.5392 mL	7.0784 mL		10 mM	0.3539 mL	1.7696 mL	3.5392 mL
	Solvent	Mass	1 mg	5 mg	10 mg																							
	Concentration																											
Preparing	1 mM	3.5392 mL	17.6960 mL	35.3920 mL																								
Stock Solutions	5 mM	0.7078 mL	3.5392 mL	7.0784 mL																								
	10 mM	0.3539 mL	1.7696 mL	3.5392 mL																								

	<p>此方案可获得 <math>\geq 2.5 \text{ mg/mL}</math> (<math>8.85 \text{ mM}</math>, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 <math>1 \text{ mL}</math> 工作液为例，取 <math>100 \mu\text{L} 25.0 \text{ mg/mL}</math> 的澄清 DMSO 储备液加到 <math>900 \mu\text{L}</math> 玉米油中，混合均匀。</p>
<b>References</b>	<p>[1]. <a href="#">Intengan HD, Smyth DD. Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance. J Pharmacol Exp Ther. 1997 Apr;281(1):48-53.</a></p> <p>[2]. <a href="#">Uhlén S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [<sup>3</sup>H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43.</a></p> <p>[3]. <a href="#">Board AW, Perry VP, Shepperson BE. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension. Clin Ther. 1988;10(6):761-75.</a></p> <p>[4]. <a href="#">Guanfacine</a></p>



# 源叶生物